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Background: Intrahepatic cholangiocarcinoma (ICC) remains a rare tumour, although its incidence is
increasing. Surgical resection is the mainstay of treatment. Published data regarding prognostic factors
and optimal patient selection for resection are scant. We sought to determine the clinicopathologic
characteristics of resectable ICC and outcomes following surgical treatment.
Methods: We reviewed prospectively collected clinical data including patient, pathologic and operative
details. Survival and recurrence outcomes were analysed using Cox hazard models and the Kaplan–Meier
method.
Results: We identified 31 surgically treated patients. Their 3-year overall survival rate (OS) was 40.1%;
median follow-up was 16.2 months (range: 0.2–86.9 months). R0 resection was associated with signifi-
cantly improved OS compared with R1/R2 resection (3-year OS was 68.6% in R0 vs. 24.0% in R1/R2; P
= 0.042). The postoperative complication rate was 58.1%. Two patients died of postoperative liver failure
within 30 days. Preoperative hypoalbuminaemia was significantly associated with worse survival.
Conclusions: Surgical therapy for ICC is associated with longterm survival in the subset of nutritionally
replete patients in whom an R0 resection can be achieved. Surgical mortality is significant in patients
undergoing extended resection. The margin involvement rate is high and surgeons should consider the
infiltrative nature of the disease in operative planning.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is second only to hepato-
cellular carcinoma (HCC) in terms of incidence of primary
hepatic tumours. It accounts for approximately 15% of primary
liver cancers and is associated with a median survival of 4.5
months from the time of diagnosis.1,2 The poor overall outcome
associated with the disease is likely to be related to a pattern of
clinical presentation in which patients remain asymptomatic until
the tumour has reached a relatively advanced stage.3 Recent
studies have clearly demonstrated an unexplained rise in the inci-
dence of ICC in the Western hemisphere.3,4 By contrast, rates of
extrahepatic cholangiocarcinoma (ECC) have either stabilized or,
in some populations, declined.1
The increasing incidence of ICC has resulted in a number of
reports describing surgical treatment and outcomes.3,5–8 However,
the majority of these reports come from a relatively few high-
volume centres and there are few data from regional treatment
centres or community hospitals involved in the treatment of this
group of patients.3,6,9
This study aimed to use pooled clinical data from hepatobiliary
programmes at an academic and a community-based hospital to
assess short- and longterm outcomes after surgical treatment of
ICC. Our analysis focuses on the identification of prognostic
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factors to assist in patient selection, as well as on the identification
of predictors of postoperative adverse events.
Materials and methods
Outcome data for patients diagnosed with ICC who underwent
surgical resection at either Oregon Health and Science University
(OHSU) or Providence Portland Medical Center (PPMC)
between January 1998 and July 2009 were prospectively collected
and retrospectively reviewed.
Study patients were identified either through the OHSU
tumour registry (January 1998 to July 2009) or the PPMC Health
Plan database (January 2002 to July 2009). Patients who were
treated non-operatively, had hilar cholangiocarcinoma or ECC
were excluded. The final study group comprised a total of 31
patients (23 from OHSU, eight from PPMC) and the study pro-
tocol was approved by the institutional review boards of both
OHSU (eIRB #5257) and PPMC (IRB #09-043A).
Patient demographics, tumour characteristics, operative data,
tumour pathology and disease recurrence were obtained from
hospital medical records. Demographic details included age,
gender, body mass index (BMI) and American Society of Anesthe-
siologists (ASA) class, as well as data on co-morbid conditions and
preoperative symptoms. Co-morbid conditions were organized
into four major categories based on diagnoses listed in a patient’s
medical record as follows: cardiac (coronary artery disease, myo-
cardial infarction, hypertension); pulmonary (congestive heart
failure, chronic obstructive pulmonary disease, asthma, chronic
bronchitis, tracheal stenosis); diabetes/obesity (either), and previ-
ous cancer (any solid organ, cutaneous or haematologic malig-
nancy). Similarly, symptoms present preoperatively were
organized into three main categories: obstructive symptoms (jaun-
dice, pruritis, elevated liver function tests); pain, and weight loss.
Postoperative complications were organized into the following
categories: cardiac (myocardial infarction, atrial fibrillation); pul-
monary (pneumonia, pulmonary effusion, respiratory failure
requiring mechanical ventilation); infectious (intra-abdominal
abscess, sepsis); biliary leak (biloma on imaging, bilious drainage
from drains), and liver insufficiency (hepatic encephalopathy,
ascites, elevated INR [international normalized ratio]). Data on
tumour characteristics, such as size, solitary vs. multiple tumours
and T stage, were also collected. Survival status was obtained from
either the hospital medical record or the social security death index.
Survival and recurrence rates were analysed by univariate Cox
proportional hazard models.Development of a postoperative com-
plication was analysed by univariate logistic regression models.
Cox or logistic models were created for each predictor variable and
outcome combination because an insufficient sample size limited
the utility of more traditional multivariate modelling. The natural
log of length of stay (LOS) was analysed with t-tests for binary
predictors, and Pearson correlations for continuous predictors.
P-values of <0.05 were considered significant. All data were analy-
sed using pasw Version 18.0 (SPSS, Inc., Chicago, IL, USA).
Results
Demographics and clinical presentation
Of the 31 surgically treated patients (10 male, 21 female), 93.5%
were symptomatic at the time of diagnosis. The most common
symptoms at presentation were unintentional weight loss (45.2%,
14/31), biliary obstruction (38.7%, 12/31) and preoperative pain
(35.5%, 11/31). The median patient age, BMI, ASA classification
and major co-morbid classes of the study population are listed in
Table 1.
Treatment
At the time of diagnosis, 93.5% (n = 29) of patients presented with
disease that appeared to be confined to either the left or right lobe
of the liver, whereas 6.5% (n = 2) of patients presented with
bilobar disease (Table 2). The mean tumour size was 6.0 cm
(range: 1.2–16.0 cm) and the majority of tumours were solitary
(93.5%, n = 29). All patients had mass-forming tumours, although
pathologic reporting of the presence or absence of periductal and
intraductal involvement was inconsistent. None of the patients
had documented capsular invasion. The presence or absence of
microvascular invasion was not consistently documented in
pathologic reports. The majority of the study patients had solitary
tumours and therefore multifocality analysis on survival was not
performed. Liver resections were classified according to the Inter-
national Hepato-Pancreato-Biliary Association Brisbane 2000
Terminology of Liver Anatomy and Resections guidelines.10 The
Table 1 Patient demographics
Variable n (%)
Mean age, years 62.3
Male gender 10 (32%)
Mean body mass index 29.4
American Society of Anesthesiologists class
Grade 1 1 (3%)
Grade 2 11 (35%)
Grade 3 12 (39%)
Grade 4 5 (16%)
Unknown 2 (6%)
Mean preoperative albumin, g/dl (range) 3.4 (1.8–4.7)
Presence of hypoalbuminaemia 11 (35%)
Co-morbid conditions
Cardiac 14 (45%)
Pulmonary 12 (39%)
Diabetes mellitus/obesity 4 (13%)
Prior history of cancer 7 (23%)
Preoperative symptoms
Obstruction 12 (39%)
Pain 11 (36%)
Unintentional weight loss 7 (23%)
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majority of patients underwent major resection (n = 29, 93.5%);
11 (35.5%) underwent extended resection.
Outcomes
Patient demographic variables, presenting symptoms, co-
morbidities, preoperative laboratory values and tumour charac-
teristics were analysed to determine predictors of specific outcome
measures, including margin status (microscopically negative
margins [R0], vs. microscopically positive [R1] or macroscopically
positive [R2] margins), LOS, development of postoperative com-
plications, and time to recurrence and mortality.
Overall survival (OS) is summarized in Fig. 1, which demon-
strates a 3-year OS of 40.1%. The median OS was 30.9 months;
median follow-up was 16.2 months (range: 0.2–86.9 months).
Median OS periods for microscopically negative margin (R0, n =
16), microscopically positive margin (R1, n = 13) and macroscopi-
cally positive margin (R2, n = 2) resections were 54.4, 19.4 and 0.6
months, respectively (P = 0.055). The short OS for R2 resections
derives from two patients, the first of whom was jaundiced at
presentation, had an LOS of 13 days and survived approximately
20 months post-resection. The second R2 patient was anicteric at
presentation and underwent an extended resection but was unable
to be rendered disease-free. This patient died on postoperative day
(POD) 19 from liver insufficiency complicated by a urinary tract
infection, which progressed to sepsis and acute renal failure. When
R0 resections were compared with R1/R2 resections, curative
resection significantly improved 3-year OS (68.6% vs. 24.0%;
P = 0.042) (Fig. 2).
When patient and tumour factors were analysed, preoperative
weight loss was found to be a significant predictor for increased
Table 2 Treatment details
Treatment variable n (%)
Tumour characteristics
Mean tumour size, cm 6.0
Lobar 29 (94%)
Bilobar 2 (6%)
Multifocal 2 (6%)
Operative details
Resection type
Extended hepatectomy 11 (35%)
Major hepatectomy 17 (55%)
Minor hepatectomy 3 (10%)
Degree of resection
R0 16 (52%)
R1 13 (42%)
R2 2 (6%)
Mean length of stay, days 16 (median 10, range 2–125)
Postoperative complications
Cardiac 1 (3%)
Pulmonary 4 (13%)
Infectious 11 (36%)
Bile leak 8 (26%)
Liver insufficiency 8 (26%)
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Figure 1 Overall survival, entire study group (n = 31)
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Figure 2 Survival in R0 vs. R1/R2 resection (P = 0.042)
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mortality (P = 0.01) and elevated preoperative total bilirubin
demonstrated a trend towards increased mortality (P = 0.05,
hazard ratio [HR] 1.102, 95% confidence interval [CI] 1.000–
1.214). Increasing tumour size did not correlate with decreasing
time to death. In patients who were rendered disease-free (R0, n =
16), 1-, 2- and 3-year recurrence-free survival rates were 77.9%,
64.9% and 48.7%, respectively. Analysis of patient and tumour
factors in this relatively small group of patients did not demon-
strate any predictors for recurrence, although the majority of
recurrences occurred in the liver.
Regional lymph node sampling and formal lymphadenectomy
were performed at the discretion of the surgeon. Patients with
pathologically confirmed node-negative disease (N0) had a 3-year
OS of 60.0% (P = 0.076), although lymph nodes were submitted
for analysis in only a third of patients (Fig. 3). When node-
negative vs. node-positive disease was analysed to determine
impact on other outcomes such as LOS or postoperative compli-
cation rate, no correlations were identified. However, there were
no recurrences in the subset of patients who underwent R0 resec-
tion with pathologically confirmed node-negative disease.
Major complications occurred in 58.1% of patients (n = 18) and
most patients suffered more than one complication. Complica-
tions are listed in Table 2. When patient, tumour and treatment
variables were assessed, none were found to correlate with the
development of a postoperative complication, although the pres-
ence of at least one co-morbidity demonstrated a trend towards an
increased complication rate, but this was not significant (P =
0.072). Two patients died from liver failure on POD 19 and POD
25, respectively. Both had undergone extended resection and had
other co-morbidities, and resection was considered to be their
only viable option. No patient in this series underwent preopera-
tive portal vein embolization.
The mean LOS for all patients was 16 days (range: 2–125 days);
when a single outlier (LOS 125 days) was removed, the mean LOS
dropped to 12 days. Mean LOS was 9 days (range: 2–15 days)
for uncomplicated procedures and 20 days (range: 7–125 days) for
complicated procedures. Analysis to identify predictors for
increased LOS showed that only an ASA level 3 was predictive
for increased LOS (P = 0.004).
Preoperative hypoalbuminaemia was associated with a median
OS of 11.0 months compared with 17.0 months in patients with
normal albumin levels (P = 0.01). When gender, albumin (normal
vs. low), co-morbidities (yes vs. no) and nodal status (positive vs.
negative/unassessed) were assessed, hypoalbuminaemia was the
only significant predictor for survival (P = 0.045, HR = 3.6).
Preoperative elevated INR was significantly associated with pre-
operative hypoalbuminaemia (P = 0.017), conferring an odds
ratio (OR) of 4.6 for every 0.1 increase in INR (95% CI 1.308–
16.150), whereas preoperative weight loss and tumour size were
not (P = 0.758 and P = 0.335, respectively).
Discussion
In this review of the clinicopathologic features of resectable ICC
tumours and patient outcomes at two regional cancer centres,
longterm survival was seen in patients in whom an R0 resection
was achieved. Few meaningful predictors for survival and
morbidity were identified and it is uncertain whether the associa-
tion of preoperative hypoalbuminaemia with worse outcomes is
reflective of nutritional status, extent of disease or a combination
of both. Extended resections in our series were associated with
morbidity and mortality, and liver failure represented a life-
threatening problem.
One of our principle findings was a high rate of R1 resections
(n = 13). The infiltrative nature of ICC is well known and can
make the achievement of negative margins technically challeng-
ing, yet this is a known important prognostic factor.3,11,12 Jonas
et al. recommend extended resections to increase the rate of cura-
tive resections.6 In their series, 60% of patients underwent
extended liver resections and R0 resections were achieved in 71%
of the total study group, conferring overall 1- and 5-year survival
rates of 72.4% and 30.4%, respectively. This was supported by
Jiang et al., who reported longterm survival in patients who
underwent extensive major hepatectomy and did not have nodal
involvement.12 In the current study, R0 resection was associated
with significantly improved OS compared with R1/R2 resection
(3-year OS 68.6% in R0 vs. 24.0% in R1/R2; P = 0.042) (Fig. 2).
Extended resection carried a relatively high morbidity rate, spe-
cifically for the development of postoperative liver insufficiency.
Recently, preoperative portal vein embolization has been used
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more frequently at both our institutions to improve the margin of
safety when subjecting patients to extended resections.
Another finding of the current study was that preoperative
hypoalbuminaemia was associated with worse survival. Preopera-
tive albumin levels are a known predictor for surgical complica-
tions and outcomes in population-level studies of non-cardiac
surgery13,14 and liver resection patients.15 Gibbs et al. demon-
strated that serum albumin was the strongest predictor of post-
operative mortality and morbidity in non-cardiac cases,14 with an
exponential increase in both morbidity and mortality rates when
albumin levels dropped below 21 g/l. Similarly, in a review of liver
resection patients, Virani et al. demonstrated that higher serum
albumin levels were associated with decreased 30-day morbidity.15
The current study demonstrated that preoperative hypoalbumin-
aemia was also associated with a significantly worse median OS
with an HR of 3.6 in the ICC patient population. There are several
possible mechanisms by which hypoalbuminaemia might nega-
tively impact survival. It may be a surrogate marker of disease
progression, although no correlation between tumour size and
albumin level was identified. Preoperative albumin levels are often
used as a marker of nutritional status, although in our study no
correlation between preoperative weight loss and hypoalbumin-
aemia was seen. Finally, albumin level may be a surrogate for
synthetic function of the liver. Preoperative elevated INR was
significantly associated with preoperative hypoalbuminaemia (P =
0.017), conferring an OR of 4.6 for every 0.1 increase in INR (95%
CI 1.308–16.150), which suggests that preoperative hypoalbumin-
aemia may reflect poor synthetic function. Regardless of the
mechanism, surgeons should be aware that marked hypoalbumin-
aemia is a marker for poor prognosis. In patients with significant
hypoalbuminaemia, consideration should be given to a brief pro-
gramme of intensive nutritional therapy. If nutritional status
cannot be optimized, patients may be best served with non-
operative treatment (involving chemotherapy, radiation or both)
rather than radical resection. These patients could be re-evaluated
for surgical candidacy at a later date if they respond to treatment.
Conclusions
Our review of regional cancer centres’ experience with ICC cor-
roborates the findings of studies carried out in national centres.3,6,9
Despite the infiltrative and aggressive nature of ICC, surgical
therapy is associated with longterm survival in the subset of
patients who are nutritionally replete and, based on our small
sample size, have node-negative disease, and in whom preopera-
tive studies suggest that an R0 resection is possible. Preoperative
portal vein embolization can be considered in order to reduce the
morbidity associated with extended liver resections.
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